Clyra is exploring working with Twist Bioscience to build its proprietary longitudinal data engine for cancer drug development, starting with osteosarcoma.
Published
Signal category
Partnerships
Quote
“An important step toward building Clyra’s proprietary longitudinal data engine for cancer drug development. We look forward to exploring this work with Twist Bioscience, starting with osteosarcoma.”
— Clyra team
Company
Clyra
Decision intelligence for oncology drug development.
- Industry
- Biotechnology Research
- Location
- San Francisco, US
- Company size
- 3 employees
Clyra is building the decision-making platform for oncology drug development. We help biopharma teams define the right patients and biomarker strategy before a trial, then identify response and resistance biomarkers to guide the next phase of development. Clyra combines human cancer data with longitudinal molecular, treatment, and outcome data from naturally occurring canine cancers. We’re starting with osteosarcoma and expanding into other rare and hard-to-model cancers.